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Mandating COVID-19 Vaccines
Severe acute respiratory syndrome coronavirus 2
(SARS-CoV-2) vaccines hold promise to control the pan-
demic and help restore normal social and economic life.
The US Food and Drug Administration (FDA) has granted
Emergency Use Authorization (EUA) for 2 messenger
RNA vaccines and will likely issue full biologics licenses
in the coming months. Anticipating vaccine scarcity, the
Advisory Committee on Immunization Practice (ACIP)
published guidance on vaccine priorities.
DataforthevaccinesgrantedanEUAreportedlydem-
onstrate 95% efficacy, but even highly effective vaccines
cannot curb the pandemic without high population cov-
erage and maintenance of other mitigation strategies.
Recent data from 1676 adults surveyed November 30 to
December 8, 2020, found that when a COVID-19 vaccine
is approved and widely available: 34% would get it as soon
as possible; 39% would wait; 9% would only get it if re-
quired for work or school; 15% would definitely not get it.
Black persons, at high risk of infection and hospitalization,
arelesslikelytoreportvaccineintentwithonly20%report-
ing they would get the vaccine soon and 52% intending to
wait.1 Intent to vaccinate has changed substantially over
time and is likely to continue to evolve. In this Viewpoint,
we examine whether vaccine mandates would be lawful
and ethical and whether they could boost vaccine uptake.
From EUAs to BLA Approvals
Mandating COVID-19 vaccines under an EUA is legally and
ethically problematic. The act authorizing the FDA to is-
sue EUAs requires the secretary of the Department of
Health and Human Services (HHS) to specify whether in-
dividuals may refuse the vaccine and the consequences
for refusal. Vaccine mandates are unjustified because an
EUA requires less safety and efficacy data than full
Biologics License Application (BLA) approval. Individu-
als would also likely distrust vaccine mandates under
emergency use, viewing it as ongoing medical research.
Should SARS-CoV-2 Vaccines Be Mandatory?
Once SARS-CoV-2 vaccines receive a BLA, policy mak-
ers must determine to which, if any, populations man-
dates should apply. Vaccine mandates could be im-
posed in multiple sectors, each with their own legal and
ethical considerations.
State Mandates | Since Jacobson v Massachusetts (1905),
the judiciary has consistently upheld vaccination man-
dates. All states require childhood vaccines as a condi-
tion of school entry, which are demonstrated to main-
tain high coverage and prevent vaccine-preventable
diseases.2 All states grant medical exemptions, and 45
states and Washington, DC, grant religious exemp-
tions, with 15 states also allowing philosophical exemp-
tions. Vaccine exemptions often cluster geographically
and socially and are associated with a higher risk of out-
breaks. Strengthening the rigor of the application pro-
cess and enforcement are associated with improved vac-
cination rates.3 Adult vaccine mandates are rare, but at
least 16 states require influenza or hepatitis B vaccina-
tions for postsecondary education. Given the rarity of
adult mandates, states are unlikely to enact mandatory
COVID-19 vaccinations for the adult population, espe-
cially in the absence of long-term safety data.
Health Care Facilities | Health care workers are at in-
creased risk of contracting infectious diseases and trans-
mitting to vulnerable populations. Consequently, health
care institutions must institute infection control proto-
cols, and many require health care workers to receive the
influenza vaccination. These institutions owe both le-
gal and ethical duties to staff and patients to ensure a
safe environment. Additionally, because vaccines pre-
vent hospitalizations, their wide use in health care set-
tings may reduce worker shortages. Even among health
workers, however, SARS-CoV-2 vaccine mandates could
be counterproductive, given the stress of working dur-
ing a pandemic. Offering nonmedical exemptions could
reduce health worker concerns over mandates.
Businesses | In a recent Yale CEO survey of 150 execu-
tives, 71% supported companies requiring COVID-19
vaccines.4 The Equal Employment Opportunity Com-
mission (EEOC) has ruled that businesses can compel
employees to submit to SARS-CoV-2 tests as a condi-
tion of employment. Recently, the agency determined
that employers can require COVID-19 vaccines and bar
employees from the workplace if they refuse.5 The
Occupational Safety and Health Administration earlier
issued guidance permitting employers to require influ-
enza vaccinations. The EEOC, however, requires em-
ployers to grant medical exemptions and offer reason-
able accommodations based on religion or disability.6
Businesses will rely on high vaccine coverage to fa-
cilitateareturntonormaloperatingpractices.Sectorsrang-
ing from food service and transportation to the arts and
sports have been economically harmed by public health
restrictions, as well as by consumer reluctance to risk
SARS-CoV-2 exposure. In many settings, like meatpack-
ing plants, there is high occupational risk of virus trans-
mission. Businesses have an ethical and legal duty to keep
their workers and customers safe. Thus, businesses that
require in-person attendance, cater to vulnerable custom-
ers, or both may consider mandates with accommoda-
tions for medical, religious, or disability reasons.
Postsecondary Education | Colleges and universities will
also need high vaccine coverage to safely reopen in-
person learning. Sitting in a crowded classroom for long
durations poses a high risk of transmission. Postsecond-
ary institutions have often been loci for vaccination
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campaigns, and many have required influenza vaccines during the
COVID-19 pandemic. It is foreseeable that institutions of higher edu-
cation may require SARS-CoV-2 vaccines for students, faculty, and
staff as part of fall 2021 reopening plans.
Primary and Secondary Education | Returning to in-person child edu-
cation is a vital social goal, given rising achievement gaps between
high- and low-income students as well as parental needs to return
to the workforce. At-home schooling is suboptimal for student learn-
ing and can cause increased mental distress in households. There
are also public health justifications for safely reopening schools. While
COVID-19 is generally less severe among children, older children are
a source of disease transmission. Teachers, moreover, are vulner-
able to SARS-CoV-2, including serious disease. Requiring SARS-
CoV-2 vaccines of schoolchildren and teachers and staff could en-
able students to safely return to in-person education.
School mandates for COVID-19 vaccines could occur, as an addi-
tion to ACIP-recommended childhood vaccinations. Yet mandates are
not warranted until the FDA licenses a vaccine with reliable data on
vaccine safety and efficacy among school-aged children. Even after
phase 3 vaccine studies among children are completed and after full
vaccine licensure is obtained, postmarketing safety monitoring is es-
sential to fully characterize the risks. In 2006, the Association of Im-
munization Managers (AIM) advised, “School and child care immuni-
zation requirements must be used sparingly, approached cautiously,
and considered only after an appropriate vaccine implementation
period.”7 At that time, AIM also recommended broad public and pro-
fessional support for any vaccine prior to implementing mandates.
Costs and vaccine supplies must also be at acceptable levels.
Vaccination as a Condition of Service
Businesses have a duty to safeguard their customers and often im-
pose safety precautions as a condition of providing services to cus-
tomers. During the pandemic, many businesses have required masks
and distancing for consumers. Even before the pandemic, custom-
ers could not enter certain premises in possession of a firearm or other
hazardous substance. It is foreseeable that businesses in certain high-
risk settings could require proof of vaccination as a condition of ser-
vice, such as in long-distance travel (plane, rail, bus), restaurants, and
entertainment (sports, movies, theater). While states might be con-
stitutionally barred from requiring vaccines to participate in religious
worship, it is conceivable that some churches, synagogues, or mosques
might consider such conditions for congregants.
Local or state governments could also require vaccination as a
condition of service. To ensure safety, research must first ascertain
whether vaccines prevent infection or only prevent disease. The du-
ration of immunity from vaccines is also unknown. Beyond gaps in
scientific knowledge, so-called “immunity passports” face logisti-
cal challenges, including implementing a novel policy approach in
the US. Any certification or immunity passport, moreover, should
be explicit about what is being attested to and avoid guarantees of
protection against COVID-19.8 If scientific and logistical challenges
can be overcome, linking vaccinations as a condition of providing ser-
vice could be an effective incentive for vaccination.
Acceptance and Implementation
Legal mandates signal clear policy support for immunizations, which
can also increase resources for a vaccine infrastructure. Yet man-
dates can undermine public support, creating a backlash and even
reducing vaccine uptake. Mandates may be useful in the future, but
their implementation among any population that does not widely
support vaccination could be counterproductive. The purpose of risk
communication is to inform decision-making, respecting individual
choice. Mandates fundamentally alter this dynamic by overriding per-
sonal autonomy. Furthermore, although employers, health care, and
educational institutions can monitor conformance with mandates,
there are no clear mechanisms to enforce population-wide vacci-
nation requirements.
Immunization coverage sufficient to achieve community im-
munity will reap enormous health, social, and economic benefits.
Limited vaccine mandates with public support, in special high-risk
or high-value settings, and with longer-term safety data can be part
of a comprehensive package of interventions to return society to pre-
pandemic life.
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